Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized, open-label study of CG1940 and CG8711 [cancer vaccine-GVAX] versus docetaxel [Taxotere] and prednisone in patients with metastatic hormone-refractory prostate cancer who are chemotherapy-naive

Next Previous
X
Search
Trial Profile

A phase III randomized, open-label study of CG1940 and CG8711 [cancer vaccine-GVAX] versus docetaxel [Taxotere] and prednisone in patients with metastatic hormone-refractory prostate cancer who are chemotherapy-naive

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL-1

    • Most Recent Events

    • 28 Feb 2009 Final results were presented at the ASCO 2009 Genitourinary Cancers Symposium.
    • 17 Oct 2008 Status changed from active, no longer recruiting to discontinued (Independent Data Monitoring Committee showed that the trial had less than 30% chance of meeting its primary endpoint).
    • 29 Sep 2008 Checked against clinicltrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top